Picture of Genexine logo

095700 Genexine Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Genexine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-48,561-57,132-66,860-63,706-27,215
Depreciation
Amortisation
Non-Cash Items33,99030,85117,80849,903-7,336
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-1,473-18,3286,0296,783-2,005
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-12,745-39,800-38,055-1,648-29,584
Capital Expenditures-57,007-31,779-7,379-7,303-14,759
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items49,30229,864-26,904-3,9148,040
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-7,704-1,915-34,283-11,217-6,719
Financing Cash Flow Items6,471-13,117-339824
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities43,08731,63260,4277,96144,211
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash22,584-9,853-11,910-4,8677,987